Why Did Neuren Pharmaceuticals (ASX:NEU), Mesoblast (ASX:MSB), and PYC Therapeutics (ASX:PYC) Rally on 5 November 2026?

Sonal Goyal

05 November 2026 06:16 PM AEDT

Why Did Neuren Pharmaceuticals (ASX:NEU), Mesoblast (ASX:MSB), and PYC Therapeutics (ASX:PYC) Rally on 5 November 2026?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• Neuren Pharmaceuticals (ASX:NEU) closed at A$23.24, surging 17.49%, after reporting Q3 2026 DAYBUE net sales up 39% year-on-year and upgrading full-year guidance.

• Mesoblast (ASX:MSB) closed at A$2.17, up 3.33%, as the company reported a 44% increase in net revenues and an 86% improvement in net operational cash spend.

• PYC Therapeutics (ASX:PYC) closed at A$1.93, gaining 4.32%, following its Q3 2026 Shareholder update detailing progress across its precision medicine pipeline.

The S&P/ASX 200 (XJO) closed at 9,065.10 on 5 November 2026, up 2.61% or 230.60 points, while the S&P/ASX 200 Health Care index (XHJ) advanced 3.64%, adding 1,240.30 points to close at 35,329.10. Overnight Wall Street gains following the Democrats' decisive midterm election victory provided a favourable global backdrop. Among ASX-listed biotechs, Neuren Pharmaceuticals Ltd (ASX:NEU) was the standout performer, surging 17.49% on same-day quarterly results, while Mesoblast Ltd (ASX:MSB) and PYC Therapeutics Ltd (ASX:PYC) also recorded gains.

Neuren Pharmaceuticals — DAYBUE Sales Accelerate

Neuren Pharmaceuticals Ltd (ASX:NEU), a biopharmaceutical company focused on neurological disorders, closed at A$23.24, surging 17.49% on 5 November 2026. The rally coincided with the company's Q3 2026 quarterly update released the same day, which reported DAYBUE net sales up 39% compared to Q3 2025. DAYBUE (trofinetide) is approved for the treatment of Rett syndrome in the United States, and the company also upgraded its full-year 2026 guidance on the back of the accelerating sales trajectory.

Neuren receives royalties and milestone payments from its partner Acadia Pharmaceuticals, which commercialises DAYBUE in the U.S. market. The Q3 update indicated continued growth in patient enrolments and prescription volumes, supporting the upward revision in Revenue expectations for the full year. Neuren is also advancing additional pipeline candidates targeting other neurological conditions.

Mesoblast — Revenue Growth and Cash Burn Improvement

Mesoblast Ltd (ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, closed at A$2.17, up 3.33%. The company released its quarterly activity report for the September 2026 quarter, reporting a 44% increase in net revenues and an 86% improvement in net operational cash spend compared to the prior year period.

Mesoblast highlighted that all patients had been treated in its MSB-DR004 pivotal Phase 3 trial of rexlemestrocel-L for inflammatory chronic low back pain (CLBP). The company also noted a positive meeting with the U.S. Food and Drug Administration regarding its development programme. Mesoblast's commercial product, RYONCIL, continues to generate revenues, while the pipeline remains focused on addressing inflammatory conditions with its cell therapy platform.

PYC Therapeutics — Pipeline Progression

PYC Therapeutics Ltd (ASX:PYC), a biotechnology company developing precision medicines for genetic diseases, closed at A$1.93, up 4.32%. The company released its Q3 2026 shareholder update on 29 October 2026, providing details on progress across its pipeline of RNA-targeting therapies.

PYC's proprietary platform is designed to deliver precision medicines to specific tissues, with a focus on conditions where no treatment currently exists. The quarterly update outlined advancement of its clinical and preclinical programmes, including updates on its lead Assets targeting inherited retinal diseases. PYC has been building its development capabilities and expanding its intellectual property portfolio to support its pipeline.

Sector Context

ASX-listed biotechs vary widely in their development stages and revenue profiles. Neuren's 17.49% gain reflects the market impact of commercial-stage data, with DAYBUE's sales trajectory providing tangible evidence of revenue generation. Mesoblast, while earlier in its commercial journey, showed improvement in both revenue and Cash Management metrics. PYC represents the pre-revenue end of the spectrum, where pipeline progression and platform validation are the primary value drivers. The broader healthcare sector's 3.64% gain on 5 November provided a supportive environment for biotech names across the development curve.

What It All Means

The three biotechs each advanced on 5 November 2026, driven by a combination of company-specific catalysts and broader market momentum. Neuren's same-day quarterly results and guidance upgrade were the clearest driver of its outperformance, while Mesoblast and PYC benefited from recent quarterly updates and the risk-on market environment. Each company occupies a different stage of the biotech lifecycle, from PYC's preclinical development through Mesoblast's late-stage trials to Neuren's commercial-stage Royalty stream.

FAQs

Q: What is DAYBUE and who makes it?

A: DAYBUE (trofinetide) is a treatment for Rett syndrome approved in the United States. It was developed by Neuren Pharmaceuticals and is commercialised by Acadia Pharmaceuticals.

Q: Why did Neuren surge 17.49% on 5 November 2026?

A: Neuren released its Q3 2026 quarterly update on the same day, reporting DAYBUE net sales up 39% year-on-year and upgrading its full-year 2026 guidance.

Q: What is Mesoblast's lead clinical programme?

A: Mesoblast's lead programme is rexlemestrocel-L, being evaluated in a pivotal Phase 3 trial (MSB-DR004) for inflammatory chronic low back pain.

Q: What does PYC Therapeutics focus on?

A: PYC develops precision medicines using its proprietary RNA-targeting platform, with a focus on genetic diseases including inherited retinal conditions.

Q: How did the ASX healthcare sector perform on 5 November 2026?

A: The S&P/ASX 200 Health Care index (XHJ) gained 3.64% to 35,329.10, outperforming the broader S&P/ASX 200 which rose 2.61%.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.